Granules India Ltd., a growing pharmaceutical manufacturing company, announced today financial results for its first quarter ended 30th June, 2017.
Quarterly Financial Highlights of Q1-FY18:
Consolidated Standalone
Revenue: Rs. 386 Cr. Rs. 396 Cr.
EBITDA: Rs. 77 Cr. Rs. 79 Cr.
Net Profit: Rs. 37 Cr. Rs. 36 Cr.
The Company's Board of Directors has approved interim dividend of 25 paise per share of face value of Re. 1 each.
Granules Omnichem Private Limited (JV) has not contributed to the profit growth for this quarter as most of the orders shall be delivered in the subsequent quarters due to cyclical nature of the business.
"I am happy to state that the current year has started with a positive note. While our journey towards transformation by developing newer avenues continues, we remain focused on strengthening our base business. Our vertical integration across core business products is one of our key strengths and it will continue to differentiate us. We shall continue to build on our strengths by commercializing additional API and PFI capacities during the year and this will enable us to maintain our steady financial performance," said Mr. Krishna Prasad Chigurupati, Chairman and Managing Director.
About Granules India Ltd. (BSE: 532482, NSE: GRANULES)
Granules India is a growing pharmaceutical manufacturing company with best-in-class facilities and is committed to operational excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which gives the customers flexibility and choice. Granules supports customers with unique value, extensive product range, and proactive solutions. The Company's global presence extends to over 250 customers in 60 countries through offices in India, U.S., and U.K.
Media Contact:
Hari Prasad Gogoikar
Concept Public Relations
[email protected]
+91-9618883774
